Beam Therapeutics Announces Closing of Initial Public Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Beam Therapeutics Inc. (Nasdaq:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the closing of its initial public offering of 12,176,471 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,588,235 additional shares of common stock, at a public offering price of $17.00 per share. The aggregate gross proceeds to Beam Therapeutics from the offerin

IPO

via https://www.AiUpNow.com

February 11, 2020 at 07:46AM by , Khareem Sudlow